

## SPINE SAFETY CAUTIONARY NOTICE:

### Information for Healthcare Professionals:

#### **Pepcid (famotidine) tablets:**

#### **Labeling Changes**

According to MedWatch, FDA notified healthcare professionals of labeling changes for Pepcid (famotidine) tablets. The following has been added to the labeling:

### **PRECAUTIONS**

- Prolonged QT interval has been reported very rarely in patients with impaired renal function whose dose/dosing interval of famotidine may not have been adjusted appropriately

### **ADVERSE REACTIONS**

#### ***Cardiovascular:***

- Prolonged QT interval, in patients with impaired renal function, has been reported very rarely

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members.

Information from these notices is also archived on the NASS website at

<http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.